NCT04714554View on ClinicalTrials.gov

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

March 29, 2021

Study Completion Date

March 29, 2021

Conditions
Healthy
Interventions
DRUG

Relugolix/E2/NETA FDC

Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.

DRUG

Relugolix

Relugolix 120-mg tablets; oral administration.

DRUG

Erythromycin

Erythromycin 500-mg tablets; oral administration.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, An Evolution Research Group Portfolio Company, Hialeah

Sponsors
All Listed Sponsors
lead

Myovant Sciences GmbH

INDUSTRY